Cargando…
Trabectedin as a single agent and in combination with pegylated liposomal doxorubicin – activity against ovarian cancer cells
Over 225 000 new cases of ovarian cancer are diagnosed each year. Symptoms are often vague, so most cases are detected when the disease is at an advanced stage. There is a need to find new drugs which will be able to treat ovarian cancer effectively. One of the most promising antineoplastic agents i...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4268992/ https://www.ncbi.nlm.nih.gov/pubmed/25520572 http://dx.doi.org/10.5114/wo.2014.43153 |
_version_ | 1782349312130285568 |
---|---|
author | Marczak, Agnieszka Denel, Marta |
author_facet | Marczak, Agnieszka Denel, Marta |
author_sort | Marczak, Agnieszka |
collection | PubMed |
description | Over 225 000 new cases of ovarian cancer are diagnosed each year. Symptoms are often vague, so most cases are detected when the disease is at an advanced stage. There is a need to find new drugs which will be able to treat ovarian cancer effectively. One of the most promising antineoplastic agents is trabectedin (Yondelis), derived from the marine tunicate Ecteinascidia turbinata, approved by the European Union in July 2007 for the treatment of soft-tissue sarcomas. This drug shows a mechanism of action based on the inhibition of the nucleotide excision repair system. Trabectedin shows anti-tumour activity in vitro and in vivo in ovarian, breast, prostate, renal, melanoma and non-small cell lung cancer cell lines. Trabectedin in combination with pegylated liposomal doxorubicin demonstrates synergistic antineoplastic activity. |
format | Online Article Text |
id | pubmed-4268992 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-42689922014-12-17 Trabectedin as a single agent and in combination with pegylated liposomal doxorubicin – activity against ovarian cancer cells Marczak, Agnieszka Denel, Marta Contemp Oncol (Pozn) Review Over 225 000 new cases of ovarian cancer are diagnosed each year. Symptoms are often vague, so most cases are detected when the disease is at an advanced stage. There is a need to find new drugs which will be able to treat ovarian cancer effectively. One of the most promising antineoplastic agents is trabectedin (Yondelis), derived from the marine tunicate Ecteinascidia turbinata, approved by the European Union in July 2007 for the treatment of soft-tissue sarcomas. This drug shows a mechanism of action based on the inhibition of the nucleotide excision repair system. Trabectedin shows anti-tumour activity in vitro and in vivo in ovarian, breast, prostate, renal, melanoma and non-small cell lung cancer cell lines. Trabectedin in combination with pegylated liposomal doxorubicin demonstrates synergistic antineoplastic activity. Termedia Publishing House 2014-06-18 2014 /pmc/articles/PMC4268992/ /pubmed/25520572 http://dx.doi.org/10.5114/wo.2014.43153 Text en Copyright © 2014 Termedia http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Marczak, Agnieszka Denel, Marta Trabectedin as a single agent and in combination with pegylated liposomal doxorubicin – activity against ovarian cancer cells |
title | Trabectedin as a single agent and in combination with pegylated liposomal doxorubicin – activity against ovarian cancer cells |
title_full | Trabectedin as a single agent and in combination with pegylated liposomal doxorubicin – activity against ovarian cancer cells |
title_fullStr | Trabectedin as a single agent and in combination with pegylated liposomal doxorubicin – activity against ovarian cancer cells |
title_full_unstemmed | Trabectedin as a single agent and in combination with pegylated liposomal doxorubicin – activity against ovarian cancer cells |
title_short | Trabectedin as a single agent and in combination with pegylated liposomal doxorubicin – activity against ovarian cancer cells |
title_sort | trabectedin as a single agent and in combination with pegylated liposomal doxorubicin – activity against ovarian cancer cells |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4268992/ https://www.ncbi.nlm.nih.gov/pubmed/25520572 http://dx.doi.org/10.5114/wo.2014.43153 |
work_keys_str_mv | AT marczakagnieszka trabectedinasasingleagentandincombinationwithpegylatedliposomaldoxorubicinactivityagainstovariancancercells AT denelmarta trabectedinasasingleagentandincombinationwithpegylatedliposomaldoxorubicinactivityagainstovariancancercells |